2025 GenScript
Biotech Global Forum

Dr. Raymond Miller is the Head of Corporate Communications. With over 12 years of experience in cross-functional communication, market research, strategy, and product development, Raymond has successfully led multiple global product management teams at GenScript. His notable achievements include building internal communication and information-sharing channels, establishing market intelligence programs, and launching nine nucleic acid reagent services.

Before joining GenScript, Raymond held various commercial and product management roles at Agilent Technologies and Bio-Rad Laboratories, where he took on increasing responsibilities. Key highlights from his tenure at these organizations include developing the SureSelect™ XT HS2 RNA Reagent Kit and globally launching the ChemiDoc™ MP Imaging system.

Dr. Raymond holds a PhD in Biochemistry and Molecular Biology from Virginia Tech.

Tom Whitehead is a keynote speaker, author, and journeyman lineman for Penelec, a FirstEnergy Company. He is also the proud father of Emily, and co-founder of the Emily Whitehead Foundation, which raises funds and awareness for pediatric cancer immunotherapy research. Tom and his wife Kari founded the Emily Whitehead Foundation in honor of their daughter Emily who was diagnosed at age five with an aggressive form of leukemia that failed to respond to chemotherapy. As a last hope, Emily was enrolled in a clinical trial and became the first pediatric patient in the world to receive CAR T-cell therapy. The therapy worked and Emily is now 11 years cancer free and considered cured.

Emily Whitehead Foundation

Carl June is a physician scientist and the Richard W. Vague Professor in Immunotherapy at the Perelman School of Medicine at the University of Pennsylvania in the Departments of Medicine and Pathology and Laboratory Medicine. He is the director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and the Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. Born in Colorado and raised in California, June graduated from the US Naval Academy and earned his medical degree in from the Baylor College of Medicine. He spent his fourth year of medical school at the World Health Organization in Geneva, Switzerland, studying immunology and malaria. June conducted postdoctoral research in transplantation biology at the Fred Hutchinson Cancer Center in Seattle from 1983 to 1986. June served as president of the Clinical Immunology Society and is a member of the American Academy of Arts and Sciences, the American Philosophical Society and both the National Academy of Sciences and the National Academy of Medicine. He is the scientific co-founder of Tmunity Therapeutics (acquired by Kite Pharma), Dispatch Biotherapeutics, Capstan Therapeutics and Bluewhale Bio. CTL019, the CAR T cell developed in the June laboratory was the first gene therapy to be approved by the US Food and Drug Administration.

June Lab

Josh Resnick is a Senior Managing Director at RA Capital Management. Josh’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities, including its incubator, Brahma Discovery. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital.

RA Captial

Caroline Stout is a Partner at EcoR1 Capital. Ms. Stout joined EcoR1 in 2014 and has led several of the firm’s investments in the biotechnology sector. She has also served as Chief Investment Officer of Panacea Acquisition Corp I and II. Prior to joining EcoR1, Ms. Stout worked as an investment banker at Credit Suisse in New York. She currently serves as a Board Member of four private biotechnology companies: Accent Therapeutics, Affinia Therapeutics, Notch Therapeutics, and Tectonic Therapeutic. Ms. Stout graduated magna cum laude from Georgetown University with a Bachelor of Arts in Economics, a Pre-Medical concentration, and Cognitive Science minor.

Vincent founded 7G BioVentures, after leading the biotech VC investments at Hillhouse ($70B AUM). Previously, He was a partner at 6 Dimensions Capital. He helped build the first institutional angel fund in the US, BioAdvance. Prior to his endeavor in private equity, he was a senior analyst and portfolio manager at Franklin Templeton Investments for 8 years, investing in biotech companies at private and public stages.

Currently, Dr. Yan Zhu is Vice President and head of global open innovation with Mitsubishi Tanabe Pharma America. Trained as an organic chemist with a Ph.D. from the Scripps Research Institute, Yan spent the bulk of his industry career in R&D function in both scientific and managerial roles with biotech/pharma, such as Genentech, Metabolex, Lilly, and Takeda. Later on, Yan crossed into the business side as head of Japan business for WuXi AppTec, and then as an executive officer and VP for Mitsubishi Tanabe Pharma Corporation responsible for Asia Business.

Alan Bash joined Legend Biotech as President, CARVYKTI in October 2024, overseeing Global Manufacturing and Supply, Quality, and Commercial Operations for the leading BCMA CAR-T on the market. Prior to joining Legend, Alan served as CEO of two oncology-focused biotech companies, most recently at ZielBio and, prior to that, at Checkmate Pharmaceuticals, which was acquired by Regeneron. Before that, Alan had a 23-year career with Bristol Myers Squibb, where he held various leadership positions across all major therapeutic areas, including Oncology, driving the expansion of products such as Opdivo, Yervoy, and Erbitux. He received his MBA from Columbia Business School and his BA from Georgetown University.

Dr. Bin Li is the founder and CIO of Lake Bleu Capital. Previously, he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley. He was recognized as the best Asia/China healthcare analyst by investor polls, including No. 1 Asia Healthcare Analyst by "Institutional Investor" (II) for seven consecutive years (2008-2014) and No.1 China Healthcare Analyst by II (2010-2014). He also was a key member of a top-rank US pharmaceutical research team at Merrill Lynch based in New York. Before that, he worked at Merck Research Laboratory as a scientist. Dr. Li holds a Ph.D. in biochemistry and MBA from New York University, and a BA in chemistry from Fudan University. Lake Bleu Capital is a Hong Kong-based investment platform that specializes in healthcare in Asia/Greater China. It manages strategies through both public and private equity with a primary focus on mid- to latestage investments. Its healthcare hedge fund won multiple industry-leading performance awards, including the AsiaHedge and the HFM Hedge Fund Asia Awards.

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development and is an author or co-author of over 125 publications. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in 2016, and is a Fellow of the American College of Physicians and a member of the National Academy of Medicine.

FDA

Multiply Labs

Sheba Global

Rey is the Chief Business Officer of Accellix and joined Accellix as its Vice President Sales and Marketing in July 2019. She has served as a Product Development and Marketing leader for the prior 14 years in both hi-tech and biotech companies. Rey has a graduate degree in Medical Research and a MBA from The University of California, Berkeley and started her career in pharmaceutical sales at Merck Pharmaceuticals. She then joined a biotech startup that was acquired by Life Technologies (Thermo Fisher) as a Field Applications Scientist (FAS) increasing customer acquisition and retention and later was promoted to a Global Product Manager role at Life Technologies, where she launched and managed instrument and consumable products in the molecular biology space. She then transitioned to a Sr. Product Marketing Manager at Illumina, where she launched and managed products in the sequencing space, and later served as the Product Marketing Director at Twist Bioscience leading the global marketing team towards commercial product launches and a successful IPO. After that, she worked at the Chan Zuckerberg Initiative (CZI) leading the Product Marketing efforts of free technological tools to advance medical research.

Accellix

Jason Bock, PhD, is CEO of CTMC, a joint venture between Resilience + MD Anderson Cancer Center. Formed in May 2022 to accelerate patient access to impactful cell therapies by bridging cell therapy development and manufacturing with MD Anderson’s clinical trial capabilities. In 2019, Jason was recruited by MD Anderson from Teva Pharmaceuticals to build the Biologics Development group. The group purchased a 60,000 SF facility in the Texas Medical Center and has since formed multiple partnerships with both MD Anderson faculty and early-stage biotech firms to bring their products through the IND process. Previously, Jason was Site Head and VP of Global CMC Biologics in the Specialty R&D Division of Teva Pharmaceuticals. He joined Teva through the acquisition of CoGenesys, a private biotech firm as a spinoff from Human Genome Sciences (HGS), where he worked after completing a PhD at Stanford University in Molecular & Cellular Physiology.

Dr. Hing C. Wong has served as the CEO since founding HCW Biologics Inc. (HCWB) in April 2018. HCWB is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related pathologies. In his expansive biotechnology career in the past 30+ years, he has founded many biopharma companies and has extensive experience in corporate management, finance, technology licensing and acquisitions, spin-offs, joint ventures, and IPO. Before HCWB, Dr. Wong founded and served as the CEO of Altor BioScience Corp. (Altor), a leading biopharmaceutical company in the development of immunotherapeutics for oncology and infectious diseases, from 2002 to August 2017. After Altor acquired in August 2017 by NantCell, Inc. (which is now ImmunityBio, Inc.), Dr. Wong served as CEO of NantCell until March 2018. At Altor/NantCell, Dr. Wong led the team to invent and develop ALT-803 (now known as Anktiva) from the bench through pivotal clinical trials. ALT-803 was approved by US FDA as a treatment for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer in April 2024. Prior to Altor, Dr. Wong founded and served as CEO of Sunol Molecular Corporation from 1996 to 2002; the Director, Biology Skills Center of Baxter Healthcare Inc. from 1992 to 1996; and the Director of Microbial Genetics of Cetus Corporation from 1983 to 1992. Dr. Wong received his Ph.D. degree in Microbiology and Immunology at the University Massachusetts, Amherst and completed his postdoctoral training at the University of Washington. Dr. Wong is the Principal Investigator of many NIH grants, an inventor of over 100 issued patents, and the lead or corresponding author of over 150 scientific publications in major, high-impact peer-reviewed journals.

HCW Biologics Inc.

Michael Vreeland joined ProBio as the US Site Head and Interim Head of Process Development, overseeing operations at the state-of-the-art manufacturing facility in Hopewell, New Jersey, which serves ProBio's North American hub for plasmid DNA and viral vector production. With over 16 years of cGMP manufacturing experience, including leadership roles at Curia, Thermo Fisher Scientific, and Sanofi Pasteur, Michael brings deep expertise in plasmid DNA, viral vectors, biologics manufacturing, and process development.

Hari Pujar is the Co-Founder and Board Director of Mirai Bio and an Operating Partner at Flagship Pioneering. He also serves as the Chief Operating Officer of Tessera Therapeutics. Hari is a global biopharmaceutical executive with over 20 years of value creation in the biologics and vaccine industry.

Before Flagship, Hari served as Chief Technology Officer of Spark Therapeutics, leading the technical operations, process and technology development and quality assurance organizations. At Spark, Hari was responsible for growing and scaling the company’s cutting-edge technology capabilities for an expanding development pipeline.

Prior to Spark, Hari was head of Technical Development & Manufacturing at Moderna Therapeutics. At Moderna, he built and led the technology and early manufacturing organizations that delivered on supply for more than a dozen clinical programs in a brand-new technology area. Previously, Hari held a variety of scientific and cross-functional leadership positions during 18+ years at Merck & Co in the company’s commercial, R&D and manufacturing divisions, culminating in the franchise leadership of pediatric and adult vaccines representing over $2B in revenue.

Hari has a PhD in Chemical Engineering from the University of Delaware and an MBA from the Wharton School at the University of Pennsylvania. He is a Fellow of the American Chemical Society and the American Institute of Medical and Biological Engineers.

Veteran editor Matthew Pillar is chief editor of Bioprocess Online and host of both the Bioprocess Online Live series of digital panel events and the weekly Business of Biotech podcast.

In his editorial capacity, Pillar has been covering the biologic therapies manufacturing space since 2019. He’s authored hundreds of columns covering the people behind the development of large molecule therapies and vaccines, primarily in the new and emerging biotech sector. Pillar has given presentations at events hosted by ISPE, BPSA, and multiple companies in the supplier community. Learn more about Bioprocess Online.

As host of Bioprocess Online Live, Pillar has brought together industry experts for dozens of live, interactive discussions on all aspects of bioprocess development, upstream and downstream manufacturing, new bioprocess technologies, and regulatory considerations. Learn more about Bioprocess Online Live.

His weekly podcast, the Business of Biotech, has produced more than 200 episodes of 1:1 conversation with the leaders of emerging biotech from around the globe. The podcast offers a roadmap to biotech formation, covering financial, legal, commercial, personnel, and scientific strategies with a veritable who’s-who of founders and executive leaders. Learn more about the Business of Biotech Podcast.

Lori Ellis is currently the head of insights at BioSpace. She analyzes industry trends within the life sciences industry. She is considered a subject matter expert in women’s health, AI, investment and DEIB clinical trial and data issues. She is the sole producer and moderator for BioSpace’s Denatured podcast, which tackles relevant topics with senior executives in a panel format. Recognized as an effective speaker, moderator, and host, she specializes in moderating authentic discussions regarding current industry challenges, their impacts on the future and how to mitigate potential future risks, designed for a senior executive audience.

Guowei Fang joined Legend Biotech in March 2022 as Senior Vice President, Global Head of Research and Early Development, and was appointed Chief Scientific Officer and Head of Business Development in December 2022.

Prior to Legend Biotech, Dr. Fang served as the Senior Vice President of Research at Zymeworks Inc., overseeing the development of novel platforms and a portfolio of multi-functional biologics and antibody-drug conjugates. Before that, Dr. Fang led discovery and early development initiatives as Head of Discovery at Pharmacyclics, an AbbVie company. In that role, he built the Research, Discovery, Translation, and Clinical Pharmacology organizations, delivered a broad pipeline of hematological assets, and supported the clinical development of IMBRUVICA®. Dr. Fang also held positions at AbbVie and Genentech with a focus on oncology research and discovery. Prior to transitioning into the pharmaceutical industry, he was a faculty member at Stanford University, leading cancer research initiatives.

Dr. Fang earned his Ph.D. from the University of Colorado and completed his postdoctoral training at Harvard Medical School. He also holds a BS in biochemistry from Nanjing University. Dr. Fang has published over 60 manuscripts in cancer research and drug discovery and development, including primary publications in Science, Nature, and Cell.

Clinician, scientist and entrepreneur, Massimiliano “Max” Paganelli is co-founder and Chief Executive Officer of Morphocell Technologies, a Montreal-based regenerative medicine company focusing on the treatment of liver disease. He is also associate professor of pediatrics at the Université de Montréal and pediatric transplant hepatologist and director of the Liver Tissue Engineering and Cell Therapy Laboratory at the CHU Sainte-Justine, in Montreal. After completing his medical studies and pediatric training in Rome, Italy, Max trained in hepatology and liver transplantation in Brussels, Belgium, obtaining a PhD from the Université catholique de Louvain. Recruited by CHU Sainte-Justine and Université de Montréal in 2015, he is a FRQS Junior 2 clinician-scientist and leads a CIHR-, NSERC- and Stem Cell Network-funded tissue engineering laboratory. His expertise focuses on the use of stem cell-derived liver tissues for the study and treatment of severe liver diseases affecting children and adults. From his lab he spun out Morphocell Technologies Inc., which he led to a $40M series A and to become one of the leading regenerative medicine start-up companies targeting liver disease.

Morphocell Technologies

Reagan Jarvis is the co-founder and CEO of Anocca, a T-cell immunotherapy company based out of Sweden, commencing FIH clinical trials in 2025 with TCR-T cell therapy products in oncology.

A New Zealander, Jarvis obtained his PhD in Biochemistry at University of Otago and performed postdoctoral research at the University of Otago and thereafter the German Cancer Research Center (DKFZ) in Heidelberg. He founded Anocca with Mikael Blomqvist in 2014.

Anocca currently has a pipeline of 40 products. It has 120+ staff, with 36 nationalities and operates the largest cGMP cell therapy manufacturing site in the Nordics.

Annoca

Louis Breton is Chief Executive Officer and a Co-Founder of Rampart Bioscience, a company focused on developing non-viral DNA gene medicines. Mr. Breton has 30 years of biotechnology leadership, most recently serving as CEO of Calimmune, a gene therapy company he launched in 2006 with Nobel Laureate David Baltimore, Ph.D., to address chronic diseases including HIV and sickle cell anemia. (Calimmune and its proprietary stem cell gene therapy platform were acquired in 2017 by CSL Behring.) Over the course of his career, Mr. Breton has built three life science companies and contributed to more than 20 product launches, as well as numerous licensing deals and regulatory negotiations. Named as one of the top 100 most inspirational and extraordinary leaders in the life sciences industry by PharmaVOICE magazine, Mr. Breton is a current or former board member of more than a dozen biotech and high-tech companies and is actively involved in numerous charitable projects. He holds a B.S. in Molecular and Cellular Biology from University of Arizona.

Daniel Shelly, Ph.D., MBA is the Chief Business Development Officer and member of the Executive Leadership Team for PolTREG where he is responsible for advancing next generation T-regulatory cell therapies for Autoimmune disease. Previously, he was the VP of Business Development and Alliances at Prescient Therapeutics where he was responsible for advancing a next-generation, modular, and post-infusion controllable CAR-Immune cell therapy platform along with small molecule targeted therapies. Previously, he was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force. He has over 19 years of biopharmaceutical BD licensing and alliance management experience.